Sidley Represents Telix Pharmaceutical in US$2.1 Billion Partnering Agreement With Regeneron

Sidley represented Australia-based Telix Pharmaceuticals on its landmark strategic collaboration with Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical therapies under a 50/50 cost and profit-sharing model, combining Telix’s radiopharmaceutical capabilities with Regeneron’s antibody and oncology experience. The agreement includes a US$40 million upfront payment to Telix for four initial programs, with potential to receive up to US$2.1 billion over the course of the agreement.

More information about the agreement is available here.

The Sidley team was led by Josh Hofheimer (Technology and Life Sciences Transactions) along with Sabrina Glavota (Technology and Life Sciences Transactions); and included Jonathan Trang (Technology and Life Sciences Transactions); Jonathan Westreich (Tax); Scott Nonaka (Global Arbitration, Trade and Advocacy); Trevor Wear (Healthcare); Evie Whiting (Global Finance); and Taylor Ishida (M&A).